ModifiedBlue Cross Blue Shield - IowaPolicy N/A

Autologous Chondrocyte Implant for Focal Articular Cartilage Lesions

Policy governing medical necessity and investigational determinations for autologous chondrocyte implantation (ACI/MACI) for focal full-thickness cartilage defects (primarily of the knee) and for combined ACI/OATS procedures; affects providers who request coverage from Wellmark/Blue Cross Blue Shield Iowa for these procedures.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyAutologous Chondrocyte Implant for Focal Articular Cartilage Lesions

Policy CodePolicy N/A

Change TypePolicy revised (most recent revision June 2025)

Effective DateMay 1, 2014

Next Review DateN/A

Key ActionSubmit prior authorization with lesion characteristics, prior treatment history, and at least 1 year of follow-up documentation to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

Policy revised during annual reviews with the most recent revisions noted in June 2025.

Recent guideline and evidence updates from AAOS (2023) and NICE (2018) are referenced for consideration in supplemental information.

15-55age range for coverage

>=1.5 cm2min lesion size

Outerbridge III-IVlesion grade

BMI>35

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Investigationalnon-knee ACI

Coverage and Clinical Criteria for ACI/MACI

Medically necessary ACI for knee lesions

Covered when ALL of the following are met:

ACI coverage criteria: Patient meets ALL of: age 15 to 55 years (adolescent individuals should be skeletally mature with documented closure of growth plates); focal, full-thickness (Outerbridge grade III or IV) unipolar lesions of the weightbearing surface of the femoral condyles, trochlea, or patella at least 1.5 cm^2 in size; documented minimal to absent degenerative changes in the surrounding articular cartilage (Outerbridge grade II or less) with normal-appearing hyaline cartilage surrounding the border of the defect; and normal knee biomechanics or alignment and stability achieved concurrently with autologous chondrocyte implantation.see node text

Adolescents must have documented growth plate closure.

Investigational / Not covered indications

Investigational indications: ACI not meeting the above knee criteria; ACI for all other joints; combined (hybrid) ACI/OATS for symptomatic full-thickness cartilage defects of the femoral articular surface or patella.

These are considered investigational because the evidence is insufficient to determine improvement in net health outcome.

Population and Intervention

Covered when ALL of the following are met

Population and intervention: Patient has focal articular cartilage lesion(s) of the weight-bearing surface of the femoral condyles, trochlea, or patella AND the proposed treatment is autologous chondrocyte implantation (including MACI) performed by an orthopedic surgeon (arthroscopy for biopsy followed by arthrotomy and implantation).

Based on PICO and intervention description in the evidence review.

Follow-up requirement

Minimum follow-up to evaluate efficacy

Minimum follow-up: At least 1 year of follow-up is considered necessary to demonstrate efficacy in reported studies.>=1 year

Existing literature lengths of follow-up range from 1 to 10 years; 1 year is the explicit minimum stated.

Evidence summaries

Summary of comparative trial and review findings relevant to coverage decisions

Key findings: Systematic reviews and network meta-analyses report that ACI/MACI may provide better outcomes than microfracture on some measures (e.g., KOOS Sport subscale improvement ~9.9 points greater than microfracture in Abraamyan et al 2022) and lower long-term failure rates for ACI versus microfracture at 10 years (Zamborsky et al 2020). Overall ranks in some analyses favored ACI variants and osteochondral autograft over microfracture, though many comparisons showed no significant differences; evidence quality ranged from poor to moderate and results vary by lesion size, patient age, and prior procedures.

Evidence statements summarized from multiple systematic reviews and meta-analyses; not prescriptive coverage criteria.

Situations supported by RCT evidence

Evidence from randomized trials demonstrates MACI is at least noninferior and in some outcomes superior to microfracture for focal knee cartilage defects meeting trial criteria.

Trial-consistent indications: Patients with symptomatic focal Outerbridge grade III–IV cartilage defects of the femoral condyles or trochlea; defect sizes in trials were generally >=3 cm^2 (SUMMIT) or 1–4 cm^2 in other RCTs; stable knee and intact or partially intact meniscus; baseline impaired KOOS (e.g., KOOS pain <55 in SUMMIT).defect size >=3 cm^2 commonly used

SUMMIT and other RCTs showed greater KOOS improvements and higher response rates for MACI versus microfracture at 2 and 5 years.

Factors associated with worse outcomes / need for caution

Observational and systematic review data identify subgroups with poorer outcomes.

Risk factors: Older age, less-active individuals, lesion size >6 cm^2, prior failed chondral treatment or prior knee surgery are associated with lower functional scores or higher failure rates.lesion size >6 cm^2 associated with poorer outcomes

Failure rates varied widely across studies; pooled mean failure ~14.9% in some reviews.

Evidence-based outcome factors and durability

Clinical findings and factors associated with ACI/MACI outcomes:

Key evidence-based factors: ACI/MACI shows better outcomes than microfracture for larger lesions and similar outcomes to osteochondral autograft for smaller lesions; defect size >4 cm^2 favors ACI in comparative studies.defect size >4 cm^2

Based on comparative and observational studies summarizing treatment effect by defect size.

Prior procedures reduce success: Prior cartilage procedures, particularly marrow-stimulation techniques (microfracture), are associated with higher failure rates and reduced graft survival (e.g., hazard ratio ~5.33 for previously treated lesions).N/A

Multiple cohort and systematic review findings indicate substantially lower survival after prior marrow stimulation.

Realignment and concomitant procedures: Correction of malalignment, patellar maltracking, and meniscal/ligamentous deficiency improves ACI outcomes; combined meniscal allograft plus cartilage repair may yield similar outcomes to procedures performed alone.

Coverage considerations

Coverage stance informed by currently available evidence:

Evidence basis for ACI in non-knee joints: Most evidence for ACI in joints other than the knee consists of case series and systematic reviews of case series; prospective comparative trials are lacking, so effectiveness is unproven for these joints (talus most commonly reported; single case series for acetabulum).

Comparative trials are needed to determine benefit.

Combined (hybrid) ACI/OATS: Current evidence for combined (hybrid) ACI/OATS is limited to case reports and small case series; no RCTs identified; prospective comparative RCTs are needed to evaluate safety and efficacy.

Insufficient evidence to support routine coverage.

Follow-up requirement: A minimum of 1 year of follow-up is considered necessary to demonstrate efficacy given variability in study follow-up durations.>=1 year

Consistent with outcomes section and requirement for demonstrating benefit.

Coverage per NICE-derived criteria

Covered when ALL of the following are met (per NICE and policy references):

General coverage criteria: Patient is an adult with a symptomatic focal articular cartilage defect (ICRS/Outerbridge grade III or IV) of the femoral condyle or patella; defect size is >2 cm^2; there has been no prior surgery to repair articular cartilage defects; and there is minimal osteoarthritic damage as assessed by an experienced clinician.defect > 2 cm^2

Derived from NICE TA508 guidance and policy discussion.

AAOS guidance consideration

Clinical uncertainty / conditional coverage considerations:

AAOS uncertainty: AAOS (2023) found insufficient evidence to recommend for or against any specific cartilage repair technique for symptomatic unsalvageable osteochondritis dissecans lesions due to heterogeneous and limited data; this uncertainty may warrant case-by-case consideration.

AAOS guideline highlights limited and heterogeneous evidence affecting technique-specific recommendations.

Misalignment and joint instability are considered contraindications to autologous chondrocyte implantation (ACI) unless corrected. The policy specifies that concurrent correction of malalignment or instability (for example, osteotomy, ligament or tendon repair) may be performed at the same time as ACI to address these contraindications and optimize the biomechanical environment for graft incorporation.

The policy notes that severe obesity (body mass index >35 kg/m^2) may adversely affect outcomes after ACI due to increased stress on weight-bearing joint surfaces and should be considered when assessing candidacy.

Product-specific regulatory labeling limits are relevant: Agili‑C is FDA‑approved for knee‑joint surface lesions with a treatable area of 1 to 7 cm^2 and without severe osteoarthritis. Lesions outside that treatable area or with severe osteoarthritic change fall outside that product indication.

There are no extensive additional procedural exclusions listed beyond the stated contraindications, but older literature noted higher complication rates with first‑generation open techniques. Clinically important exclusion considerations include uncontrolled malalignment/instability (unless corrected) and severe osteoarthritis; contemporaneous procedures (e.g., meniscal allograft transplantation) may be performed concurrently or staged as clinically indicated.

Systematic reviews and meta-analyses report heterogenous results and multiple pooled outcomes are non‑significant or not reported. Many meta-analyses show high heterogeneity (I2 frequently high) and several pooled estimates are NR; overall the literature does not provide definitive, consistent superiority of ACI/MACI across all outcomes, limiting broad generalizability of pooled results.

Observational and case‑series data identify patient and lesion factors associated with worse outcomes: specifically, large lesions (commonly cited as >6 cm^2), older or less‑active patients tend to have lower functional improvement and higher failure rates in reported series.

Reported study follow-up durations vary widely, but the policy specifies that a minimum of 1 year of follow-up is considered necessary to demonstrate efficacy of ACI; shorter follow-up is insufficient for definitive efficacy assessment.

Procedures for which the evidence base is limited to case reports or small case series — for example combined (hybrid) ACI/OATS for large knee defects — are considered investigational. The policy explicitly states that combined ACI/OATS is investigational because available evidence is limited to case studies and no RCTs or systematic reviews of RCTs exist to establish improvement in net health outcome.

Per NICE guidance excerpted in the policy, patients with more‑than‑minimal osteoarthritic damage are excluded from eligibility; NICE recommends ACI only when there is minimal osteoarthritic damage as assessed by experienced clinicians.

ACI for joints other than the knee and combined (hybrid) ACI/OATS procedures are considered investigational. The policy summarizes that evidence for non‑knee joints is primarily case series and that comparative trials are lacking, so ACI outside the knee or as combined ACI/OATS is not established as medically necessary.

Marrow stimulation techniques such as microfracture remain commonly used comparators. The policy notes that microfracture induces fibrocartilage formation, which is mechanically inferior and may degenerate over time; in some clinical settings microfracture may be preferred as an initial, less invasive option depending on lesion and patient factors.

The document does not include explicit blanket 'not medically necessary' declarations, but systematic reviews report mixed or non‑significant comparative findings for many outcomes. Those mixed or nonsignificant comparative results are noted as part of the evidence context and may influence case‑level determinations.

When comparative pooled effects are nonsignificant or when short‑term results favor less invasive options, the evidence base supports treating ACI/MACI as non‑preferred in those contexts. Several meta-analyses show no significant differences at certain follow-up points and high heterogeneity, which supports consideration of less invasive validated treatments first in some cases.

Use of ACI in older, less‑active patients and for very large lesions (>6 cm^2) is associated with poorer outcomes and higher failure rates in observational series and may be considered not medically necessary without supportive clinical rationale or individualized justification.

Multiple studies report substantially worse outcomes when ACI is performed after prior failed marrow‑stimulation procedures. For example, cohort data show markedly higher failure rates and reduced long‑term graft survival after prior marrow stimulation, indicating prior treatments materially affect expected benefit.

Combined or hybrid ACI/OATS remains investigational because the published evidence is limited to case reports and small case series and no prospective randomized controlled trials have been identified to evaluate safety and efficacy compared with ACI or OATS alone.

Prior treatments and surgical history are material to benefit assessments. Stakeholder input and multiple cohort analyses indicate prior knee surgery or prior cartilage interventions (especially marrow stimulation) significantly affect outcomes and should be documented and considered during preauthorization and case review.

Procedure and Supply Codes, Clinical Thresholds

Procedure CPT CodesCPT

27412	Autologous chondrocyte implantation, knee.
27599	Unlisted procedure, femur or knee.

HCPCS/Supply CodesHCPCS

J7330	Autologous cultured chondrocyte, implant.
S2112	Arthroscopy, knee surgical for harvesting cartilage (chondrocyte cells).

Body mass index — BMI threshold affecting outcomes

BMI thresholdSevere obesity (e.g., body mass index >35 kg/m^2) may negatively affect outcomes and is noted as a consideration for ACI candidacy.

Clinical implicationIncreased stress on weight-bearing surfaces from BMI >35 kg/m^2 may worsen outcomes; consider weight optimization prior to ACI.

Policy guidance sourcePolicy guidelines explicitly cite BMI >35 kg/m^2 as a factor that may affect outcomes.

Lesion minimum size — minimum lesion area for covered knee ACI

Minimum lesion area for coverage>= 1.5 cm^2 (focal, full-thickness unipolar lesions must be at least 1.5 cm^2 for knee ACI coverage)

Lesion grade requirement

Prior Authorization, Documentation Requirements, and Authorization Risk

Documentation Required

Prior approval / Documentation Note

Prior Approval / Documentation Note: Prior approval is not applicable for this policy, but detailed clinical documentation should be submitted with requests for ACI to support medical necessity and facilitate review. Operative reports (arthroscopy biopsy and implantation operative notes), imaging reports (MRI or CT arthrogram with lesion measurements), and documentation of alignment/stability corrections when performed should be included.

Submit operative notes for both stages (arthroscopy biopsy and implantation)
Include MRI or CT arthrogram with measured lesion size and weight‑bearing surface location
Document concurrent realignment or stabilization procedures if performed

Note

Prior authorization not stated in evidence sections

Prior authorization: Not explicitly stated in the evidence summaries. Although the policy lists medical‑necessity criteria for ACI, the evidence sections summarize trials and outcomes and do not themselves define operational prior authorization rules — use the policy criteria and required documentation to adjudicate requests.

Clinical Background and Scope

Articular cartilage defects have limited intrinsic healing capacity and can progress to pain, functional impairment, and osteoarthritis. Conventional marrow‑stimulation techniques produce fibrocartilage with inferior mechanical properties; surgical options such as osteochondral grafting and ACI/MACI aim to restore hyaline‑like cartilage. ACI involves arthroscopic biopsy of healthy cartilage, in vitro chondrocyte expansion and implantation (MACI uses a bioresorbable collagen matrix), typically performed as a staged procedure with postoperative rehabilitation.

Definitions and Terminology

Autologous chondrocyte implantation (ACI/MACI) — procedure definition and brief description

Procedure definitionAutologous chondrocyte implantation (ACI) is a cell-based cartilage repair technique in which chondrocytes are harvested from a patient’s healthy cartilage, expanded in vitro, and implanted into a chondral defect.

MACI variantMatrix-induced ACI (MACI) seeds autologous chondrocytes onto a bioresorbable collagen membrane (scaffold) for implantation; MACI is technically easier than first-generation ACI.

Typical stagingProcedure is commonly staged: arthroscopy with biopsy followed by arthrotomy for implantation and postoperative rehabilitation.

Outerbridge classification — grading system for cartilage lesions

Grade 0Normal cartilage.

Grade I

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyAutologous Chondrocyte Implant for Focal Articular Cartilage Lesions

Policy CodePolicy N/A

Change TypePolicy revised (most recent revision June 2025)

Effective DateMay 1, 2014

Next Review DateN/A

Key ActionSubmit prior authorization with lesion characteristics, prior treatment history, and at least 1 year of follow-up documentation to support medical necessity.

SourceLink

On This Page

Observational data support improved outcomes when biomechanical issues are addressed.

Durability metrics: Reported graft survival estimates approximate 78.2% at 5 years and 50.7% at 10 years (pooled cohorts); failure rates vary across studies (0%–43%) and mean time to failure ~26 months where reported.N/A

Kaplan-Meier and cohort analyses provide durability estimates.

Complications of note: Graft hypertrophy has been observed (e.g., up to 26% in some series) with unclear long-term impact on graft stability and function.N/A

Reported in randomized trials and observational follow-up; long-term significance uncertain.

Outerbridge Classification grade III or IV required for covered lesions.

Anatomic surfaceWeightbearing surface of the femoral condyles, trochlea, or patella.

Lesion size threshold — SUMMIT and trial-enrolled lesion sizes and worse outcomes >6 cm2

SUMMIT trial enrollment sizeSUMMIT enrolled defects ≥3 cm^2 (average lesion size 4.8 cm^2; range 3–20 cm^2)

Other RCT lesion rangesOther randomized trials included defects in the ~1–4 cm^2 range.

Poorer outcomes thresholdObservational and systematic-review data identify substantially worse outcomes and higher failure rates for lesions >6 cm^2.

Minimum follow-up duration — recommended evidence minimum

Minimum follow-up duration>= 1 year — a minimum of 1 year of follow-up is considered necessary to demonstrate efficacy in reported studies.

Typical follow-up range in literatureReported follow-up durations in studies range from 1 to 10 years.

Procedure staging noteACI is typically performed as a staged procedure (arthroscopy for biopsy followed by arthrotomy for implantation); outcome follow-up should extend at least 1 year.

Defect size threshold — additional defect-size threshold referenced

Additional defect-size threshold>4 cm^2 referenced as predictive: defect size >4 cm^2 was identified as a factor favoring ACI over alternatives in some studies.

ContextSome systematic reviews and cohort studies used >4 cm^2 to indicate lesions where ACI may have improved outcomes versus microfracture or other techniques.

Implication for selectionLarger defects (>4 cm^2) may more strongly support ACI consideration; very large defects (>6 cm^2) have worse outcomes and require caution.

Evidence summaries do not substitute for submission requirements
Adjudicators should apply the policy’s criteria and required documentation when determining authorization

Prior Authorization

Prior authorization: Clinical comparators and study‑aligned documentation

Prior authorization: Clinical comparators and study‑aligned documentation should be provided. Because many studies compare ACI/MACI with microfracture (MF) and osteochondral autograft transfer (OAT), include documentation of prior conservative care and any prior marrow stimulation or grafting procedures to align with comparator evidence.

Document prior conservative treatments (physical therapy, injections) and duration
Document any prior surgical cartilage procedures (microfracture, drilling, OAT) including dates and outcomes
Provide lesion characteristics (size, location, grade) consistent with trial inclusion criteria

Documentation Required

Prior treatment history required for case assessment

Prior treatment history is required for case assessment. Prior knee surgeries, especially prior marrow stimulation (microfracture/drilling), negatively affect ACI outcomes and graft survival and must be documented. Requests for ACI after failed prior cartilage procedures should include prior procedure details and outcomes.

Specify prior cartilage procedures, dates, and reason for failure
If prior microfracture or marrow stimulation was performed, document lesion response and time since procedure
Note that prior marrow stimulation is associated with higher ACI failure rates

Prior Authorization

Prior authorization for ACI (FDA‑approved products)

Prior authorization for ACI (including FDA‑approved products such as MACI and Agili‑C) is implied for surgical ACI services reported with CPT/HCPCS codes; submit clinical justification demonstrating that policy medical‑necessity criteria are met.

Use CPT 27412 (ACI, knee) and HCPCS J7330 (autologous cultured chondrocyte, implant) as applicable
Provide clinical justification tied to policy criteria (age, lesion size/location/grade, OA status, biomechanics)
Identify the specific ACI product (e.g., MACI, Agili‑C) and regulatory status

Denial Risk

Documentation‑based denial risk

Documentation‑based denial risk: Missing or incomplete documentation is a common trigger for denial. Requests lacking lesion measurements, confirmation of weight‑bearing surface location, imaging, operative notes, or documentation of biomechanics/alignment/stability correction may be denied.

Denial risk if lesion size, grade, or location not documented
Denial risk if imaging or arthroscopy documentation of the defect is absent
Denial risk if OA/RA status or alignment/stability documentation is missing

Note

Authorization implications — evidence summary only

Authorization implications — evidence summaries do not define operational rules. The body of evidence (systematic reviews, RCTs, observational studies) informs clinical criteria in the policy but does not replace the need to verify that each request meets the policy’s documented medical necessity criteria.

Apply policy criteria (age, lesion characteristics, OA status, biomechanics) when reviewing requests
Use evidence summaries to inform clinical judgment but require documentation matching policy criteria

Note

Evidence heterogeneity may affect coverage determinations

Evidence heterogeneity may affect coverage determinations. Meta‑analyses and systematic reviews report high heterogeneity (I2) across trials and variable follow‑up durations, which may limit generalizability; reviewers should consider study quality, lesion sizes studied, and follow‑up when applying evidence to individual cases.

High I2 in pooled analyses (functional outcomes) indicates heterogeneity across trials
Consider differences in lesion size, patient age, prior procedures, and follow‑up length when applying evidence

Note

Impact of prior procedures on outcomes

Impact of prior procedures on outcomes: Prior marrow stimulation (microfracture/drilling) and prior chondral treatments substantially reduce ACI graft survival and functional outcomes. Document prior interventions and consider their impact when assessing medical necessity and expected benefit.

Prior microfracture is associated with higher failure rates and lower long‑term graft survival
Primary ACI has better survival than ACI after prior marrow stimulation; quantify prior treatment history in request

Denial Risk

Procedures supported only by case studies may be investigational

Procedures supported only by case studies (e.g., combined ACI/OATS) are considered investigational. Combined (hybrid) ACI with OAT currently has only case series/case reports and limited observational data — prospective comparative trials are lacking.

Combined ACI/OATS considered investigational due to limited evidence
Case reports show promising functional improvements but lack comparative RCT data

Denial Risk

Potential triggers for denial

Potential triggers for denial: Noncompliance with stated policy criteria (age outside 15–55 years without skeletal maturity documentation, lesion size/grade/location not meeting requirements, presence of OA/RA, uncorrected biomechanical/ alignment issues), inadequate documentation, or requests for investigational combined procedures.

Denial if age or growth‑plate closure not documented for adolescents
Denial if lesion is not a focal, full‑thickness unipolar defect of weight‑bearing surface or if size <1.5 cm2 (or other policy limits)
Denial if OA/RA present or surrounding cartilage shows degenerative changes >grade II
Denial for combined ACI/OATS (investigational) or other joints not covered

Documentation Required

Required documentation

Required documentation: To support authorization, submit progress notes/history, operative reports (arthroscopy biopsy and implantation), imaging reports with lesion measurements, documentation of prior conservative and surgical treatments, and reports confirming alignment, stability, and absence of significant osteoarthritis or inflammatory arthropathy.

Progress report, history, and prior treatments (conservative and surgical)
Arthroscopy biopsy report and implantation operative note
MRI or CT arthrogram with measured lesion size and weight‑bearing surface location
Documentation of knee alignment, stability, and OA/RA assessment
Pre‑ and post‑treatment outcome scores (KOOS, VAS, IKDC) and follow‑up visits (minimum 1 year)

Note

Documentation — evidence sections vs. submission requirements

Documentation — evidence‑only sections summarize trials and systematic reviews and do not specify procedural documentation requirements. Use the policy’s Required Documentation section to determine what must be provided with an authorization request.

Evidence summaries inform clinical context but are not a substitute for operative and imaging reports
Ensure submission includes the specific documents listed in Required Documentation

Note

Submit systematic review metrics

Submit systematic review metrics when relevant to the request: when trials or meta‑analyses are cited by the treating clinician, include study counts, patient populations, lesion sizes, follow‑up durations, and outcomes to support applicability to the individual case.

If citing systematic reviews or meta‑analyses, indicate number of included studies, total N, lesion sizes studied, and follow‑up durations
Explain applicability of cited evidence to the patient’s lesion characteristics and prior treatment history

Documentation Required

Procedure staging and expected follow‑up

Procedure staging and expected follow‑up: ACI is typically a staged procedure (stage 1 arthroscopy for biopsy, stage 2 implantation). Provide documentation of both stages and objective follow‑up data; a minimum of 1 year of follow‑up is generally necessary to demonstrate efficacy in the literature.

Document both arthroscopy biopsy and implantation operative reports
Provide baseline and follow‑up outcome measures (KOOS, IKDC, VAS) with at least 1 year of follow‑up when available
Include rehabilitation protocol and postoperative visits

Documentation Required

Clinical documentation should include lesion details and baseline measures

Clinical documentation should include lesion characteristics, prior treatment history, baseline functional scores, and response to conservative care. Trial eligibility often required specific lesion sizes, grades, and locations — documentation should mirror those details to demonstrate applicability.

Lesion size (cm2), location (weight‑bearing femoral condyle, trochlea, patella), and Outerbridge grade
Baseline patient‑reported outcomes (KOOS, IKDC, VAS) and activity level (Tegner)
Prior conservative treatments and duration, prior surgical interventions and outcomes

Step Therapy

Prior surgical procedure considerations and comparator procedures

Prior surgical procedure considerations and comparator procedures: Clinical input varied on whether a prior surgical procedure is required before ACI. Many reviewers and guideline authorities recommend considering conservative or less invasive alternatives (debridement, microfracture, marrow stimulation, OAT) first in many cases, but expert input generally advises that lesions >4 cm2 may not require prior marrow stimulation.

Consider conservative care and marrow stimulation procedures as comparators; document attempts and outcomes
Clinical input is mixed on mandating prior surgery; many reviewers do not require prior procedure for lesions >4 cm2
When prior marrow stimulation was performed and failed, document timing and outcomes

Step Therapy

Step therapy / previous treatment considerations

Step‑therapy / previous treatment considerations: Evidence shows MF often yields poorer long‑term outcomes compared with ACI for larger lesions, but step‑therapy policies may still expect attempts at conservative or less invasive alternatives first. Clinical input on requiring inadequate response to prior surgery was mixed; apply policy criteria and case specifics when evaluating step‑therapy.

For lesions <3–4 cm2, microfracture is a common comparator and may be reasonable before ACI in some cases
For larger lesions (≥3–4 cm2), evidence supports ACI over MF and reviewers often recommend not requiring prior MF
Document prior therapies and rationale if skipping less invasive options

Softening and swelling.

Grade IIFragmentation and fissures in area less than 0.5 inch in diameter.

Grade IIIFragmentation and fissures in area larger than 0.5 inch in diameter.

Grade IVExposed subchondral bone.

MACI — definition and description

MACI definitionMatrix-induced autologous chondrocyte implantation (MACI) consists of autologous chondrocytes cultured onto a bioresorbable collagen membrane and implanted into the defect, often secured with fibrin glue.

Regulatory statusMACI received FDA approval (December 2016) as the marketed autologous chondrocyte implantation product in the United States.

Clinical advantageMACI eliminates the need for suturing a periosteal patch and is considered technically easier and less time-consuming than first-generation ACI.

Carticel — first-generation FDA-approved cultured chondrocyte product

Product identityCarticel® was the first-generation FDA-approved cultured autologous chondrocyte product (approved 1997) for symptomatic femoral condyle defects; production was phased out in 2017.

Current availabilityAs of document sources, MACI is the only autologous chondrocyte implantation product available in the U.S. following Carticel discontinuation.

ACI / MACI general definition

General definitionACI/MACI: a cell-based cartilage repair technique using autologous cultured chondrocytes implanted into a cartilage defect, sometimes delivered on a scaffold or matrix.

GenerationsFirst-generation ACI used periosteal or collagen covers with injected cells; second/third-generation techniques use scaffolds/matrices (e.g., MACI).

Clinical purposeIntended to regenerate hyaline-like cartilage for focal full-thickness defects that do not heal spontaneously.

Microfracture (MF) — definition

DefinitionMicrofracture (MF) is a marrow-stimulation technique that creates small fractures in the subchondral bone to stimulate fibrocartilaginous repair tissue formation.

Outcome noteMicrofracture often yields fibrocartilage that may deteriorate over time and has been associated with higher long-term failure rates compared with ACI in some analyses.

ACI / MACI short label

Short label (ACI/MACI)ACI / MACI (autologous chondrocyte implantation; matrix-induced ACI)

Common usageUsed interchangeably in literature to refer to autologous chondrocyte–based cartilage repair, with MACI indicating matrix/scaffold delivery.

MF short label

Short label (MF)MF (microfracture)

Comparator roleCommon comparator in randomized trials and meta-analyses of cartilage repair techniques.

OAT — osteochondral autograft transfer definition

OAT definitionOAT (osteochondral autograft transfer) transfers osteochondral cores from a donor site to the defect to restore contour and mechanical function.

Clinical noteOften considered for smaller defects and compared with ACI/MACI in trials and reviews.

Matrix-induced ACI (MACI) — definition and technique notes

Technique descriptionMatrix-induced ACI (MACI) seeds autologous chondrocytes onto a bioresorbable collagen membrane (scaffold) which is cut to size and fixed (commonly with fibrin glue) into the defect.

AdvantagesEliminates periosteal patch suturing required in earlier ACI and can reduce operative time and morbidity.

Clinical trial useMACI was the implant evaluated in pivotal trials such as SUMMIT comparing MACI to microfracture for larger defects.

Bilayer MACI (Sandwich technique) — definition

Use caseApplied in cases with substantial bone loss where restoration of both cartilage and subchondral bone is required.

MACI / matrix-induced ACI — second-generation ACI description

Second-generation ACIMACI and other matrix-based approaches are characterized as second-generation ACI where chondrocytes are seeded onto a bioresorbable collagen sponge/membrane before implantation.

Clinical impactSecond-generation techniques aimed to simplify implantation and avoid periosteal harvest and suturing required by first-generation methods.

AMIC — autologous membrane-induced chondrogenesis definition

AMIC definitionAutologous membrane-induced chondrogenesis (AMIC) is a cell-free technique evaluated primarily for talus cartilage repair; it uses a membrane combined with marrow-stimulation approaches.

Evidence contextMost evidence for AMIC comes from case series and small comparative studies in ankle/talus; not broadly established for knee ACI indications.

combined (hybrid) ACI/OATS — brief definition

DefinitionCombined (hybrid) ACI/OATS involves transfer of osteochondral cores to restore contour followed by overlaying with periosteal graft under which cultured chondrocytes are injected to fill remaining areas.

Evidence statusCurrent evidence is limited to case reports and small series; no RCTs identified — considered investigational pending comparative trials.

NICE eligibility criteria (excerpt) — NICE recommendations for ACI eligibility

NICE eligibility — patient populationAdults with symptomatic articular cartilage defects of the femoral condyle or patella (ICRS grade III or IV).

Prior cartilage surgeryPerson has not had previous surgery to repair articular cartilage defects (no prior cartilage repair surgery).

Osteoarthritis requirementThere is minimal osteoarthritic damage to the knee as assessed by experienced clinicians.

Defect size thresholdDefect is over 2 cm^2.

AAOS guidance summary — AAOS 2023 guidance synopsis

AAOS 2023 conclusionAAOS 2023 was unable to recommend for or against any specific cartilage repair technique for symptomatic unsalvageable osteochondritis dissecans lesions due to insufficient and heterogeneous evidence.

Evidence rationaleInsufficient and heterogeneous studies (different techniques, outcomes, and follow-up) led to inconclusive recommendations.

ImplicationAAOS guidance highlights uncertainty and may support case-by-case consideration rather than blanket endorsement of ACI techniques.